1,2-bis(3,5-dioxopiperazin-1-yl)ethane has been researched along with icrf 193 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andoh, T; Ikegami, Y; Ishida, R; Tanabe, K | 1 |
| Andoh, T; Ishida, R; Miki, T; Narita, T; Sato, M; Tanabe, K; Utsumi, KR; Yui, R | 1 |
| Chadwick, DP; Clark, JR; Ferrans, VJ; Hasinoff, BB; Herman, EH; Zhang, J | 1 |
| Higashihara, M; Honma, Y; Niitsu, N | 1 |
| Jensen, LH; Jensen, PB; Nitiss, JL; Renodon-Cornière, A; Sehested, M; Søkilde, B; Sørensen, TK | 1 |
| Grauslund, M; Jensen, LH; Jensen, PB; Sehested, M; Sorensen, TK | 1 |
6 other study(ies) available for 1,2-bis(3,5-dioxopiperazin-1-yl)ethane and icrf 193
| Article | Year |
|---|---|
Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
Topics: Antineoplastic Agents; Diketopiperazines; DNA; Piperazines; Razoxane; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 1991 |
Inhibition of intracellular topoisomerase II by antitumor bis(2,6-dioxopiperazine) derivatives: mode of cell growth inhibition distinct from that of cleavable complex-forming type inhibitors.
Topics: Cell Cycle; Cell Division; Cell Nucleus; Diketopiperazines; DNA Damage; Humans; Mitosis; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Razoxane; Spindle Apparatus; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 1991 |
Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Topics: Animals; Antibiotics, Antineoplastic; Cardiovascular Agents; Chelating Agents; Diketopiperazines; DNA Topoisomerases, Type II; Doxorubicin; Ethylenediamines; Glycine; Heart; Hydrolysis; Iron; Male; Myocardium; Piperazines; Rats; Rats, Inbred SHR; Razoxane | 1997 |
The catalytic DNA topoisomerase II inhibitor ICRF-193 and all-trans retinoic acid cooperatively induce granulocytic differentiation of acute promyelocytic leukemia cells: candidate drugs for chemo-differentiation therapy against acute promyelocytic leukem
Topics: Antineoplastic Agents; Catalysis; Cell Cycle; Cell Differentiation; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cytarabine; Daunorubicin; Deoxycytidine; Diketopiperazines; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Granulocytes; HL-60 Cells; Humans; Leukemia, Promyelocytic, Acute; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Razoxane; Receptors, Retinoic Acid; Retinoic Acid Receptor alpha; RNA, Messenger; RNA, Neoplasm; Topoisomerase II Inhibitors; Tretinoin; Tumor Cells, Cultured; U937 Cells | 2002 |
Probing the role of linker substituents in bisdioxopiperazine analogs for activity against wild-type and mutant human topoisomerase II alpha.
Topics: Adenosine Triphosphate; Antigens, Neoplasm; Catalysis; Diketopiperazines; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Genetic Complementation Test; Humans; Indoles; Isoindoles; Mutagenesis, Site-Directed; Piperazines; Razoxane; Topoisomerase II Inhibitors; Yeasts | 2003 |
Separation of bisdioxopiperazine- and vanadate resistance in topoisomerase II.
Topics: Adenosine Triphosphatases; Amino Acid Substitution; Antigens, Neoplasm; Diketopiperazines; DNA; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance; Humans; Kinetics; Piperazines; Razoxane; Topoisomerase II Inhibitors; Vanadates | 2005 |